Molgramostim
Showing 51 - 75 of 135
Malignant Melanoma, Metastatic Trial in San Francisco, Rochester (Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF),
Completed
- Malignant Melanoma, Metastatic
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
- Ipilimumab
-
San Francisco, California
- +1 more
Mar 17, 2020
Multiple Myeloma Trial in Baltimore, Philadelphia (hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion)
Completed
- Multiple Myeloma
- hTERT vaccine, GM-CSF, PCV, T cell infusion
- GM-CSF, PCV, T cell infusion
-
Baltimore, Maryland
- +1 more
Oct 21, 2019
Colorectal Cancer, Metastatic Cancer Trial in Baltimore (Colon GVAX, cyclophosphamide)
Completed
- Colorectal Cancer
- Metastatic Cancer
- Colon GVAX
- cyclophosphamide
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aug 12, 2019
Thin Endometrium Trial in Hangzhou (GM-CSF, 17-ß estradiol)
Unknown status
- Thin Endometrium
- GM-CSF
- 17-ß estradiol
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital
Sep 20, 2019
Prostate Cancer Trial in San Francisco, Baltimore, Madison (pTVG-HP, rhGM-CSF)
Completed
- Prostate Cancer
- pTVG-HP
- rhGM-CSF
-
San Francisco, California
- +2 more
Jan 15, 2021
Kidney Cancer, Lung Cancer, Metastatic Cancer Trial in Detroit (biological, other, procedure)
Completed
- Kidney Cancer
- +3 more
- sargramostim
- +4 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Feb 18, 2020
Neuroblastoma Trial in New York (Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor),
Completed
- Neuroblastoma
- Anti-GD2 3F8 Monoclonal Antibody
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 17, 2020
Ovarian Cancer, Endometrial Cancer, Fallopian Cancer Trial in Annandale (E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster,
Completed
- Ovarian Cancer
- +3 more
- E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster
- +6 more
-
Annandale, VirginiaMid-Atlantic Gynecologic Oncology & Pelvic Surgery Associates
Apr 28, 2020
Breast Cancer, Ovarian Cancer Trial in Houston (E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine)
Completed
- Breast Cancer
- Ovarian Cancer
- E39 peptide vaccine
- +2 more
-
Houston, TexasUniversity of Texas M.D. Anderson Cancer Center
Mar 16, 2020
Multiple Myeloma, Minimal Residual Disease, High-Risk Cancer Trial in New York (WT1 Analog Peptide Vaccine, Sargramostim
Unknown status
- Multiple Myeloma
- +2 more
- WT1 Analog Peptide Vaccine
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 6, 2020
Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis Trial in Belfast (Molgramostim, Placebo)
Completed
- Pulmonary Alveolar Proteinosis
- +3 more
- Molgramostim
- Placebo
-
Belfast, United KingdomCelerion
Feb 20, 2017
Stage IV Melanoma, Stage III Melanoma Trial in United States (Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC),
Terminated
- Stage IV Melanoma
- Stage III Melanoma
- Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
- Autologous PBMCs in GM-CSF (MC)
-
Irvine, California
- +17 more
May 9, 2019
Bladder Cancer, High Grade, Non Muscle Invasive Trial in Phoenix (oncolytic adenovirus expressing GMCSF)
Withdrawn
- Bladder Cancer
- +2 more
- oncolytic adenovirus expressing GMCSF
-
Phoenix, ArizonaBCG Oncology
Jan 30, 2019
Breast Cancer Trial in United States (Herceptin, NeuVax vaccine, GM-CSF)
Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection Trial (Sargramostim 0.04 mcg/kg/dose, Sargramostim
Withdrawn
- Acute Respiratory Distress Syndrome
- +2 more
- Sargramostim 0.04 mcg/kg/dose
- +2 more
- (no location specified)
Apr 15, 2019
Peripheral Arterial Disease Trial in Chicago (behavioral, other, drug)
Completed
- Peripheral Arterial Disease
- Supervised Treadmill Exercise Therapy
- +2 more
-
Chicago, IllinoisNorthwestern University Feinberg School of Medicine
Jan 10, 2020
Malignant Pleural Mesothelioma Trial in New York (WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF (This arm is
Completed
- Malignant Pleural Mesothelioma
- WT-1-vaccine Montanide + GM-CSF
- Montanide adjuvant + GM-CSF (This arm is closed)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Nov 1, 2018
Prostate Cancer Adenocarcinoma in Situ Trial in Baltimore (degarelix acetate, Cyclophosphamide, GVAX)
Completed
- Prostate Cancer Adenocarcinoma in Situ
- degarelix acetate
- +2 more
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 18, 2019
NSCLC Trial in Wuhan (Stereotactic body radiotherapy, rhGM-CSF)
Withdrawn
- Carcinoma, Non-Small-Cell Lung
- Stereotactic body radiotherapy
- rhGM-CSF
-
Wuhan, Hubei, ChinaZhongnan hospital of Wuhan university
Oct 10, 2018
Glioblastoma Trial in Worldwide (APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF)
Completed
- Glioblastoma
- APVAC1 vaccine plus Poly-ICLC and GM-CSF
- APVAC2 vaccine plus Poly-ICLC and GM-CSF
-
Copenhagen, Denmark
- +5 more
Aug 6, 2018
Prostate Cancer Metastatic Trial in Worldwide (biological, drug, other)
Completed
- Prostate Cancer Metastatic
- PROSTVAC-V
- +4 more
-
Anchorage, Alaska
- +219 more
Aug 22, 2019
Leukemia Trial in Houston (GM-CSF (Sargramostim), Rituximab)
Completed
- Leukemia
- GM-CSF (Sargramostim)
- Rituximab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 18, 2018
Metastatic Colorectal Cancer Trial in Fuzhou (Irinotecan, Oxaliplatin, Levoleucovorin)
Withdrawn
- Metastatic Colorectal Cancer
- Irinotecan
- +5 more
-
Fuzhou, Fujian, ChinaRongbo Lin
Mar 23, 2018
Malignant Glioma Trial in United States (CDX-110 with GM-CSF, Temozolomide)
Completed
- Malignant Glioma
- CDX-110 with GM-CSF
- Temozolomide
-
Orange, California
- +33 more
Jan 11, 2018
